Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Unicycive Therapeutics (UNCY) reported third-quarter results and an FDA target action date of March 25, 2027, for oxylanthanum carbonate (OLC). The FDA accepted the resubmitted new drug application in October following a June 2026 Complete Response Letter citing manufacturing-vendor deficiencies, without requesting additional clinical data. Approval remains pending.
Third-quarter net loss widened to $6.997 million from $6.011 million a year earlier, while loss per share narrowed to $0.25 from $0.33. Research and development expense fell to $2.246 million; general and administrative expense rose to $6.595 million. Cash, cash equivalents and marketable securities totaled approximately $59 million at September 30, 2026. Unicycive expects funding beyond 2027, including a potential OLC launch, and plans commercial-leadership hires in the first quarter of 2027. Separate OLC reimbursement remains conditional on FDA approval and CMS eligibility confirmation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.OLC application resubmission accepted by FDA, with a March 25, 2027 target action date.
- Moderate pointJune 2026 FDA response raised no clinical efficacy or safety concerns and requested no additional data.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Liquidity totaled approximately $59 million at September 30, 2026; Unicycive expects runway beyond 2027, including potential launch costs.
- Moderate point. Forward-looking: it has not happened yet and may not happen.OLC could receive two years of separate reimbursement at 100% of average sales price, subject to FDA approval and CMS confirmation.
- Minor pointThird-quarter R&D expense fell to $2.246 million from $2.964 million a year earlier.
3 minor points
- Minor pointThird-quarter other income rose to $1.844 million from $1.331 million a year earlier, primarily reflecting warrant revaluation.
- Minor point. Forward-looking: it has not happened yet and may not happen.Commercial preparations include planned leadership hires in first-quarter 2027 and sales-force hiring if OLC receives approval.
- Minor point. Forward-looking: it has not happened yet and may not happen.CMS finalized a $12.85 per-treatment binder-funding addition effective January 1, 2027; Unicycive sees favorable potential launch conditions.
Negative
- Moderate pointThird-quarter net loss widened to $6.997 million from $6.011 million; loss per share narrowed to $0.25 from $0.33.
- Moderate pointOLC approval remains subject to FDA review following manufacturing-vendor deficiencies cited in the June 2026 response.
- Moderate pointCommon shares outstanding rose to 29,110,352 at September 30, 2026, from 22,114,245 at December 31, 2025.
- Minor pointThird-quarter G&A expense rose to $6.595 million from $4.378 million, including $1.4 million more in launch preparation.
- Minor point. Forward-looking: it has not happened yet and may not happen.New manufacturing vendor pre-approval inspection remains uncertain; Unicycive does not know whether FDA will require one.
- Minor pointOLC reimbursement eligibility remains subject to FDA classification and applicable CMS requirements.
News Explained
OLC could get two years of reimbursement at 100% of average sales price alongside binder base funding, subject to FDA approval and CMS eligibility.
The third-quarter balance sheet reports 29,110,352 common shares outstanding on
CMS set a
The company says its TDAPA view rests on a Type 2 NDA classification, which the FDA alone will determine at approval; TDAPA eligibility is also subject to CMS requirements.
Key Figures
- PDUFA target action date
- March 25, 2027
- OLC NDA resubmission accepted; remains subject to FDA review
- Cash, equivalents and marketable securities
- Approximately $59 million
- As of September 30, 2026
- Expected cash runway
- Beyond 2027
- Includes anticipated increased expenses related to a potential OLC launch
- Phosphate binder base-rate addition
- $12.85 per treatment
- Effective January 1, 2027
- Potential TDAPA reimbursement
- 100% of average sales price for two years
- Conditional on FDA approval and CMS confirmation of eligibility
- R&D expense
- $2.2 million vs. $3.0 million
- Quarter ended September 30, 2026 vs. same period in 2025
- G&A expense
- $6.6 million vs. $4.4 million
- Quarter ended September 30, 2026 vs. same period in 2025
- Net loss attributable to common stockholders
- $(7.0) million, or $(0.25) per share, vs. $(6.0) million, or $(0.33) per share
- Quarter ended September 30, 2026 vs. same period in 2025
Previous Earnings Reports
-
June CRL cited manufacturing deficiencies; NDA resubmission remained contingent on a successful vendor inspection.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
new drug application (nda) regulatory
pdufa regulatory
complete response letter (crl) regulatory
cgmp regulatory
tdapa financial
505(b)(2) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027
- As of September 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled
$59 million , with expected runway beyond 2027, including the cost of potential OLC launch
MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”
Key Highlights & Upcoming Milestones
- OLC NDA Resubmission: In October, the Company announced that the FDA has accepted the resubmission of its NDA for OLC and set a PDUFA target action date of March 25, 2027. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026, which cited deficiencies previously identified at the original Drug Product (DP) vendor. The June 2026 CRL did not raise concerns regarding clinical efficacy or safety data or request additional data from the Company. The resubmitted NDA remains subject to FDA review.
- The NDA resubmission includes CMC data from a new DP manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status. The Company does not know whether the FDA will decide to conduct a pre-approval inspection of this DP vendor.
- The original DP vendor was recently inspected by the FDA. If the FDA finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to align with the FDA on whether that determination could shorten its review timeline and potential approval.
- Commercial Readiness: In preparation for the potential launch of OLC, Unicycive continues to advance its commercial readiness initiatives:
- Discussions with dialysis organizations as part of the OLC launch planning.
- The Company is in active discussions with key commercial leaders, with plans to bring them on board in the first quarter of 2027 and, if OLC is approved by the FDA, expects to hire an optimized sales force to target the physician prescriber base.
- Unicycive is also focused on optimizing patient access across all reimbursement settings and plans to provide dedicated access and services through its UniSource™ support hub.
On October 28, 2026, the Centers for Medicare & Medicaid Services (CMS) issued its calendar year 2027 End-Stage Renal Disease Prospective Payment System final rule, establishing permanent phosphate binder funding within the dialysis bundled payment through a$12.85 per-treatment addition to the base rate effective January 1, 2027, following the expiration of separate transitional payments for existing binders. CMS also finalized a hyperphosphatemia clinical quality measure beginning with payment year 2029, based on 2027 performance, reinforcing the importance of sustained phosphorus control. Unicycive believes that these changes create favorable commercial launch conditions for OLC, if approved. Subject to FDA approval and CMS confirmation of Transitional Drug Add-on Payment Adjustment (TDAPA) eligibility, OLC could potentially qualify for two years of separate reimbursement at100% of average sales price while dialysis providers continue to receive the new funding for binders embedded in the base rate.
- TDAPA Eligibility: Unicycive believes OLC meets the criteria for the TDAPA upon FDA approval:
- OLC qualified for a 505(b)(2) regulatory path because it contains an active moiety (lanthanum) that was previously approved; however, OLC contains a new active ingredient, oxylanthanum carbonate, that was not previously approved. The Company believes this supports Type 2 NDA classification under the FDA’s Manual of Policies and Procedures 5018.2, NDA Classification Codes.
- The determination of OLC’s NDA classification rests solely with the FDA and remains subject to the agency’s determination of NDA classification at the time of approval. The Company believes OLC, if approved, would qualify for TDAPA, subject to meeting applicable CMS requirements.
Financial Results for the Quarter Ended September 30, 2026
Research and Development (R&D) expense was
General and Administrative (G&A) expense was
Other income (expense) was
Net loss attributable to common stockholders, basic and diluted, for the quarter ended September 30, 2026, was
Cash, cash equivalents and marketable securities were approximately
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Unicycive Therapeutics
media@unicycive.com
SOURCE: Unicycive Therapeutics, Inc.
| Unicycive Therapeutics, Inc. | ||||||||
| Balance Sheets | ||||||||
| (in thousands, except for share and per share amounts) | ||||||||
| As of | As of | |||||||
| December 31, | September 30, | |||||||
| 2025 | 2026 | |||||||
| Assets | (Unaudited) | |||||||
| Current assets: | ||||||||
| Cash | $ | 29,198 | $ | 41,966 | ||||
| Prepaid expenses and other current assets | 7,692 | 10,187 | ||||||
| Marketable securities | 12,071 | 17,006 | ||||||
| Total current assets | 48,961 | 69,159 | ||||||
| Right of use asset, net | 108 | 519 | ||||||
| Property and equipment, net | 66 | 255 | ||||||
| Total assets | $ | 49,135 | $ | 69,933 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 383 | $ | 1,030 | ||||
| Accrued liabilities | 1,523 | 3,380 | ||||||
| Warrant liability | 16,915 | 12,377 | ||||||
| Operating lease liability - current | 117 | 522 | ||||||
| Total current liabilities | 18,938 | 17,309 | ||||||
| Operating lease liability - long term | - | - | ||||||
| Total liabilities | 18,938 | 17,309 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Series A-2 Prime preferred stock, | - | - | ||||||
| Series B-2 preferred stock, | - | - | ||||||
| Preferred stock, | - | - | ||||||
| Common stock, | 22 | 29 | ||||||
| Accumulated other comprehensive loss | (1 | ) | (26 | ) | ||||
| Additional paid-in capital | 158,001 | 201,988 | ||||||
| Accumulated deficit | (127,825 | ) | (149,367 | ) | ||||
| Total stockholders’ equity | 30,197 | 52,624 | ||||||
| Total liabilities and stockholders’ equity | $ | 49,135 | $ | 69,933 | ||||
| Unicycive Therapeutics, Inc. | ||||||||
| Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except for share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2025 | 2026 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 2,964 | $ | 2,246 | ||||
| General and administrative | 4,378 | 6,595 | ||||||
| Total operating expenses | 7,342 | 8,841 | ||||||
| Loss from operations | (7,342 | ) | (8,841 | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | 279 | 503 | ||||||
| Interest expense | (15 | ) | - | |||||
| Change in fair value of warrant liability | 1,067 | 1,341 | ||||||
| Total other income (expenses) | 1,331 | 1,844 | ||||||
| Net loss | (6,011 | ) | (6,997 | ) | ||||
| Other comprehensive loss: | ||||||||
| Unrealized loss on marketable securities, net | - | (3 | ) | |||||
| Net comprehensive loss | $ | (6,011 | ) | $ | (7,000 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.33 | ) | $ | (0.25 | ) | ||
| Weighted-average shares outstanding used in computing net loss per share | 18,065,389 | 28,270,842 | ||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is the FDA decision date for Unicycive's OLC application?
The FDA assigned March 25, 2027 as the target action date for Unicycive's resubmitted OLC application. Acceptance of the application does not constitute approval; the application remains under FDA review.
How long does Unicycive expect its cash to fund operations?
Unicycive expects its approximately $59 million in cash, cash equivalents and marketable securities at September 30, 2026, to fund operations beyond 2027. That expectation includes anticipated increased expenses for an OLC launch should the treatment receive approval.
What manufacturing information did Unicycive include in the OLC resubmission?
The resubmission includes chemistry, manufacturing and controls data from a new drug-product vendor. That vendor's facility received “No Action Indicated” status after its March 2024 FDA inspection. Unicycive does not know whether FDA will conduct a pre-approval inspection.
Could an inspection of Unicycive's original OLC manufacturer shorten the FDA review?
Unicycive plans to discuss a potentially shorter review with FDA if the original vendor's facility is found compliant with current Good Manufacturing Practice requirements. The original vendor was recently inspected, but no shorter review timeline or earlier approval has been established.
Why does Unicycive believe OLC could qualify for separate Medicare reimbursement?
Unicycive believes OLC's new active ingredient supports Type 2 new drug application classification and potential Transitional Drug Add-on Payment Adjustment eligibility. Its active moiety, lanthanum, was previously approved, but oxylanthanum carbonate was not. FDA controls the classification decision at approval, and eligibility also depends on applicable CMS requirements.